BRAIN Biotech Liabilities 2025

BRAIN Biotech Aktienanalyse

What does BRAIN Biotech do?

The company BRAIN Biotechnology Research and Information Network AG is a German company specializing in biotechnology. The company was founded in 1993 and is headquartered in Zwingenberg, Germany. BRAIN has been listed on the Frankfurt Stock Exchange since 2006 and has over 500 employees worldwide. The history of BRAIN dates back to the 1980s when the Senckenberg Institute for Biodiversity and Climate Research in Frankfurt developed a new method for isolating microorganisms. These are called extremophilic bacteria and fungi, which live in extreme environments such as hot springs or salty soils and produce special enzymes. These enzymes can be used in various applications, such as the food industry or the development of new drugs. BRAIN has further developed this method and built an extensive portfolio of enzymes, microorganisms, and natural substances. The company is divided into three areas: 1. BioIndustrial: Enzymes and microorganisms for industrial applications are developed here, such as for the production of detergents, paper, or bioethanol. 2. BioScience: This area focuses on the research of natural substances and active ingredients from microorganisms for the pharmaceutical and cosmetics industries. 3. Consumer Products: BRAIN develops products for end consumers here, such as probiotics or enzyme preparations for digestion promotion. BRAIN works closely with leading companies to develop innovative solutions for their needs. The company is not only focused on the development of new products but also on the optimization of existing processes. BRAIN relies on sustainable and environmentally friendly production. An example of a product developed by BRAIN is an enzyme used in the production of fruit juice. This enzyme breaks down pectin, which is found in many types of fruit and causes the juice to become cloudy. By using this enzyme, the juice can be made clearer and more durable without the need for artificial additives. BRAIN also uses a special enzyme in the production of soy milk to improve taste and consistency. Overall, BRAIN has filed over 600 patents and works with more than 170 customers in various industries. The company is committed to preserving biodiversity and promoting sustainability in production. In summary, BRAIN Biotechnology Research and Information Network AG is a company specializing in the research and development of enzymes, microorganisms, and natural substances. The company has a long history and can look back on successful collaborations with leading companies in various industries. BRAIN focuses on sustainability and environmental compatibility in production and has a broad portfolio of products that can be used in various applications. BRAIN Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing BRAIN Biotech's Liabilities

BRAIN Biotech's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating BRAIN Biotech's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing BRAIN Biotech's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

BRAIN Biotech's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in BRAIN Biotech’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about BRAIN Biotech stock

What is the level of liabilities of BRAIN Biotech this year?

BRAIN Biotech has a debt balance of 49.17 M EUR this year.

What were the liabilities of BRAIN Biotech compared to the previous year?

The liabilities of BRAIN Biotech have increased by 1.68% increased compared to the previous year.

What are the consequences of high debt for investors of BRAIN Biotech?

High liabilities can pose a risk for investors of BRAIN Biotech, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in BRAIN Biotech?

Low liabilities mean that BRAIN Biotech has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of BRAIN Biotech affect the company?

An increase in liabilities of BRAIN Biotech can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of BRAIN Biotech affect the company?

A decrease in the liabilities of BRAIN Biotech can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of BRAIN Biotech?

Some factors that can influence the liabilities of BRAIN Biotech include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of BRAIN Biotech so important for investors?

The liabilities of BRAIN Biotech are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can BRAIN Biotech take to modify the liabilities?

To change its liabilities, BRAIN Biotech can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does BRAIN Biotech pay?

Over the past 12 months, BRAIN Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BRAIN Biotech is expected to pay a dividend of 0 EUR.

What is the dividend yield of BRAIN Biotech?

The current dividend yield of BRAIN Biotech is .

When does BRAIN Biotech pay dividends?

BRAIN Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BRAIN Biotech?

BRAIN Biotech paid dividends every year for the past 0 years.

What is the dividend of BRAIN Biotech?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is BRAIN Biotech located?

BRAIN Biotech is assigned to the 'Commodities' sector.

Wann musste ich die Aktien von BRAIN Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BRAIN Biotech from 1/18/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 1/18/2025.

When did BRAIN Biotech pay the last dividend?

The last dividend was paid out on 1/18/2025.

What was the dividend of BRAIN Biotech in the year 2024?

In the year 2024, BRAIN Biotech distributed 0 EUR as dividends.

In which currency does BRAIN Biotech pay out the dividend?

The dividends of BRAIN Biotech are distributed in EUR.